

Crohn's & Colitis Foundation Visiting IBD Fellowship 2019-2020

Professional Education Resources & Reading List 2019

[Professional Reading list](#)

Professional Reading List 2019

Section: Practice Guidelines

Gastroenterology. 2015 May; 148 (5):1035-1058.e3.

Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
Bressler B¹, Marshall JK², Bernstein CN³, Bitton A⁴, Jones J⁵, Leontiadis GI², Panaccione R⁶, Steinhart AH⁷, Tse F², Feagan B⁸;

Gastroenterology. 2018 Dec 18. pii: S0016-5085(18)35407-6. **American Gastroenterological Association Institute Guideline on the Management of Mild-to-Moderate Ulcerative Colitis**. Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee.

Gastroenterology. 2019 Jan 16. pii: S0016-5085(18)35437-4. **Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group**.. doi: 10.1053/j.gastro.2018.12.022. Mahadevan U1, Robinson C2, Bernasko N3, Boland B4, Chambers C4, Dubinsky M5, Friedman S6, Kane S7, Manthey J8, Sauerban J9, Stone J5, Jain R10

Section: Treatment Strategies

Clinical Gastroenterol Hepatology. 2015 Jun;13(6):1042-1050.e2.

Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease.

Bouguen G¹, Levesque BG², Feagan BG³, Kavanaugh A⁴, Peyrin-Biroulet L⁵, Colombel JF⁶, Hanauer SB⁷, Sandborn WJ⁸.

Gut. 2013 Nov; 62(11):1523-8. **The management of immunosuppression in patients with inflammatory bowel disease and cancer**. Bernheim O¹, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH.

ACG Clinical Guideline:018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27. **Management of Crohn's Disease in Adults**. Am J Gastroenterol. 2 Lichtenstein GR1, Loftus EV2, Isaacs KL3, Regueiro MD4, Gerson LB5, Sands BE6

Gastroenterology. 2012 Jan;142(1):63-70. **Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped**. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives.

Am J Gastroenterol. 2015 Sep;110(9):1324-38. **Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target**.

Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Geary R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF.

Gastroenterology. Volume 153 , Issue 3 ,827-834. **American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease**. Feuerstein, Joseph D.Gerson, Lauren et al.

Gastroenterology. 2015 Jul;149(1):238-45. **Ulcerative Colitis Care Pathway**. Dassopoulos T1Cohen RD2Scherl EJ3Schwartz RM4Kosinski L5Regueiro MD6

Section: Treatment/Biologics

N Engl J Med. 2013 Aug 22; 369(8):711-21.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group.

Gut. 2014;63(3):433-41.

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

Travis SP, Danese S, Kupcinkas L, Alexeeva O, D'Haens G, Gibson PR et al.

The New England journal of medicine. 2005;353(23):2462-76.

Infliximab for induction and maintenance therapy for ulcerative colitis.

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al.

Gastroenterology. 2014 Feb;146(2):392-400. **Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.**

Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P.

N Engl J Med. 2013 Aug 22;369(8):699-710. **Vedolizumab as induction and maintenance therapy for ulcerative colitis.**

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group.

Cochrane Database Syst Rev. 2016 Jul 3;7:CD008870. **Aminosalicylates for induction of remission or response in Crohn's disease.** Lim WC, Wang Y, MacDonald JK, Hanauer S.

Cochrane Database Syst Rev. 2016 Apr 21;4:CD000543. **Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.** Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK.

Cochrane Database Syst Rev. 2016 May 9;(5):CD000544. **Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.** Wang Y, Parker CE, Feagan BG, MacDonald JK.

Gastroenterology. 2019 Jan;156(1):36-42. **Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.** Hanauer SB, Sandborn WJ, Lichtenstein GR.

N Engl J Med 2004;350:876-85. **Infliximab Maintenance Therapy for Fistulizing Crohn's Disease** Bruce E. Sands, M.D., Frank H. Anderson, M.D., Charles N. Bernstein, M.D., William Y. Chey, M.D., D.Sc., Brian G. Feagan, M.D., Richard N. Fedorak, M.D., Michael A. Kamm, M.D., Joshua R. Korzenik, M.D., Bret A. Lashner, M.D., Jane E. Onken, M.D., Daniel Rachmilewitz, M.D., Paul Rutgeerts, M.D., Ph.D., Gary Wild, M.D., Ph.D., Douglas C. Wolf, M.D., Paul A. Marsters, M.S., Suzanne B. Travers, M.D., Marion A. Blank, Ph.D., and Sander J. van Deventer, M.D., Ph.D

The Lancet Volume 359, ISSUE 9317, P1541-1549, May 04, 2002. **Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial** Stephen B Hanauer, MD et al The ACCENT I Study Group.

Gastroenterology. 2012;142(2):257-65 e1-3. doi:10.1053/j.gastro.2011.10.032.

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC et al

Cochrane Database of Systematic Reviews. 5:CD012540, 2018 May 12. Drug holiday management (when to stop, how to resume). **Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.** [Review] Boyapati RK; Torres J; Palmela C; Parker CE; Silverberg OM; Upadhyaya SD; Nguyen TM; Colombel JF.

Current Gastroenterology Reports. 20(8):35, 2018 Jul 02. **De-escalation of Therapy in Inflammatory Bowel Disease.** Frias Gomes C; Colombel JF; Torres J.

Section: New Therapies

Therapeutic Advances in Gastroenterology. 2015;8(2):66-82.

Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therapeutic advances in gastroenterology.

Amiot A, Peyrin-Biroulet L.

Gastroenterology. 2014 Dec;147(6):1296-1307.e5.

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.

Adedokun OJ¹, Sandborn WJ², Feagan BG³, Rutgeerts P⁴, Xu Z⁵, Marano CW⁵, Johanns J⁵, Zhou H⁵, Davis HM⁵, Cornillie F⁶, Reinisch W⁷.

New England Journal of Medicine. 2016;374:1754-1762. **Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.** William J. Sandborn, M.D., Brian G. Feagan, M.D., Douglas C. Wolf, M.D., Geert D'Haens, M.D., Ph.D., Severine Vermeire, M.D., Ph.D., Stephen B. Hanauer, M.D., Subrata Ghosh, M.D., Heather Smith, M.B.A., Matthew Cravets, M.A., Paul A. Frohna, M.D., Ph.D., Richard Aranda, M.D., Sheila Gujrathi, M.D., and Allan Olson, M.D., for the TOUCHSTONE Study Group

New England Journal of Medicine. 2017 May 4;376(18):1723-1736.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J;

New England Journal of Medicine. 376(18):1723-1736, 2017 05 04. **Tofacitinib for Ulcerative Colitis - A Promising Step Forward.** Friedman S.

New England Journal of Medicine. 2016 Nov 17;375(20):1946-1960.

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P;

Section: Imaging/Diagnostics

Gastroenterology. 2013 Jun;144 (7):1349-52, 1352.e1-6. doi: 10.1053/j.gastro.2013.04.008. Epub 2013 Apr 11.

The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease.

Soetikno R¹, Subramanian V, Kaltenbach T, Rouse RV, Sanduleanu S, Suzuki N, Tanaka S, McQuaid K.

Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R et al. **SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease.** Gastroenterology. 2015;148(3):639-51 e28. doi:10.1053/j.gastro.2015.01.031.

Section: Microbiome

Cell Host Microbe. 2014 Mar 12; 15(3):382-92.

The treatment-naïve microbiome in new-onset Crohn's disease.

Gevers D¹, Kugathasan S², Denson LA³, Vázquez-Baeza Y⁴, Van Treuren W⁵, Ren B⁶, Schwager E⁶, Knights D⁷, Song SJ⁵, Yassour M¹, Morgan XC⁶, Kostic AD¹, Luo C¹, González A⁵, McDonald D⁵, Haberman Y³, Walters T⁸, Baker S⁹, Rosh J¹⁰, Stephens M¹¹, Heyman M¹², Markowitz J¹³, Baldassano R¹⁴, Griffiths A¹⁵, Sylvester F¹⁶, Mack D¹⁷, Kim S¹⁸, Crandall W¹⁸, Hyams J¹⁶, Huttenhower C¹⁹, Knight R²⁰, Xavier RJ²¹.

Nature. 2014 Jan 23; 505(7484):559-63.

Diet rapidly and reproducibly alters the human gut microbiome.

David LA¹, Maurice CF², Carmody RN², Gootenberg DB², Button JE², Wolfe BE², Ling AV³, Devlin AS⁴, Varma Y⁴, Fischbach MA⁴, Biddinger SB³, Dutton RJ², Turnbaugh PJ².

Selected Topics: Extraintestinal Manifestations

Gastroenterology & hepatology. 2013;10(10):585-95.

Extraintestinal manifestations and complications in IBD. Nature reviews
Ott C, Scholmerich J.

Selected topics: Pouch

Surg Endosc. 2013 Nov; 27(11):4325-32.

Clinical value of surveillance pouchoscopy in asymptomatic ileal pouch patients with underlying inflammatory bowel disease. Zhu H¹, Wu XR, Queener E, Kiran RP, Remzi FH, Shen B.

Gastroenterol Clin North Am. 2012 Jun; 41(2):355-78.

Evaluating pouch problems.

Li Y¹, Shen B.

Selected topics: Health Maintenance

Am J Gastro. 2017. Feb; 112(2):241-258. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.
Farraye FA1Melmed GY2Lichtenstein GR3Kane SV4

Clinical Gastroenterology and Hepatology , Volume 16 , Issue 12 , 1872 – 1875. **The Who and Why of Herpes Zoster Vaccination in Patients With Inflammatory Bowel Diseases.** Caldera, Freddy, Farraye, Francis A.Kane, Sunanda et al.

Selected topics: Epidemiology

Lancet 2018; 390:2769–2778. **Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.** Ng SC, Shi HY, Hamidi N, et al.

Selected topics: Postoperative Crohn's

Gastroenterology. 2017 Jan; 152(1):271-275.

American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S;

Gastroenterology. 2017 Jan; 152(1):277-295.e3. doi: 10.1053/j.gastro.2016.10.039. Epub 2016 Nov 10.

American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection. Regueiro M, Velayos F, Greer JB, Bougatsos C, Chou R, Sultan S, Singh S.

Gastroenterology. 2016 Jun; 150(7):1568-78.


Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.

Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P

Selected topics: Special Populations

Gastro epub ahead.**Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group.** Mahadevan, Uma et al.

Inflamm Bowel Dis. 2018 Dec 22. doi: 10.1093/ibd/izy376. **The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy.** Lin SC1, Goldowsky A2, Papamichael K1, Cheifetz AS1.



Arthritis & Rheumatology. 68(10):2403-11, 2016 10. **Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.** Mamtani R; Clark AS; Scott FI; Brensinger CM; Boursi B; Chen L; Xie F; Yun H; Osterman MT; Curtis JR; Lewis JD.

Inflammatory Bowel Diseases. 23(6):882-893, 2017 06. **Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.** Ananthakrishnan AN; Donaldson T; Lasch K; Yajnik V.